

ATTORNEY DOCKET NO. 17451.002.03US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jean-Michael Scherrman et al

Serial No.: 10/045,971

Filed: January 9, 2002

For: Cocaethylene immunogens and antibodies

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

BOX DD

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This Supplemental Information Disclosure Statement is hereby submitted in accordance with 37 CFR 1.98(a)(2)(iii) requiring submission of copies of cited pending U.S. patent applications, and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

Please find a copies of references A1-A3 previously listed on the PTO-1449 submitted on January 9, 2002. Copies of all references have been submitted

CERTIFICATE OF FIRST CLASS MAILING

Signature:

Printed Name:

Quiano

Mayor

PATENT

ATTORNEY DOCKET NO. DASI.002.03US

that the information submitted herewith is in fact material.

The subject application is believed patentable over any of the above references.

Respectfully submitted,

Dated: march +, LOOZ

Barbara Rae-Venter, Ph.D.

Reg. No. 32,750

Rae-Venter Law Group, P.C. PO Box 1898

Monterey, CA 93942-1898

Phone: (831) 648-3090 Facsimile: (831) 242-0137

BRV/cs

PATENT



COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Sheet 1 of 2

]

In re the application of: Jean-Michael Scherrman, et al.]

Art Unit: Not Yet Assigned

Serial No. Not Yet Assigned

Examiner: Not Yet Assigned


Filed: January 9, 2002

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's <u>Initials</u>	Document Number	<u>Date</u>	Name	Class/ <u>Subclass</u>	Filing Date
Al		3,917,582	11/4/75	Soffer et al	260/121	6/13/73
A2		4,045,420	8/30/77	Soffer et al	260/121.R	5/29/73
A3		3,888,866	6/10/75	Leute et al	260/292	6/1/73
A4		5,817,770	10/6/98	Scherrmann et al	530/389.8	
A5		5,202,270	4/13/93	Ungemach et al	436/537	
A6		5,760,184	6/2/1998	Swain et al	530/387.1	11/28/199

PENDING U.S. PATENT DOCUMENTS						
Ref.	Examiner's					
Desig.	Initials	Document Number	<u>Name</u>	Filing Date		
B1		WO 96/30049	10/3/96	WIPO		
B2		WO 91/19980	12/26/91	WIPO		
B3		0467783	1/22/92	EP		
B4		0475783	3/18/92	EP		
B5		WO 93/12111	6/24/93	WIPO		

Examiner:	Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



ECEIVED SAPR 1 9 2002 CENTER 1600/29



COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FORM PTO-1449 (Modified). LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Sheet <u>2</u> of <u>2</u>

In re the application of: Jean-Michael Scherrman, et al.]

Art Unit: Not Yet Assigned

Serial No. Not Yet Assigned

Examiner: Not Yet Assigned

Filed: January 9, 2002

FOREIGN PATENT DOCUMENTS

Ref. Desig. Examiner's

Initials

Document Number

Date

Country

Class/ Subclass

Filing Date

NONE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref.

Examiner's

Desig.

Initials

C1

Oyler et al (Oct 1996) Analytical Toxicology 20:6:453-62.

277	•	
Exam	inor	
Lizain	HICI.	

ATTORNEY DOCKET NO. DASI.00 130 SUS

APR 16	AND AND THE PROPERTY OF THE PR	IN THE UNITED STATES PATENT	' A Ì	ND TRADEMARK OFFICE	CENTER 1600/2900
CATEN	applica	tion of: Jean-Michael Scherrman et al)	Examiner:	500/25
Seri	ial No.:	10/045,971)	Art Unit:	8
File	d: Janua	ary 9, 2002)	SUPPLEMENTAL INFORMATE DISCLOSURE STATEMENT	<u> TION</u>
For:	Cocaeth	nylene immunogens and antibodies)	TRANSMITTAL	
Ass	shington,	ommissioner for Patents D.C. 20231 smitted herewith is:			
	[X]	A Supplemental Information Disclosi	ıre	Statement.	
	[X] A copy of PTO-1449 previously submitted on January 9, 2002.				
	[X]	Copies of references A1-A3 as listed 2002.	on 1	the PTO-1449 submitted on January	79,
	[] An International Search Report.				
	[X]	Return postcard (postage prepaid).			

CERTIFICATE OF FIRST CLASS MAILING

Printed Name: Courney Mayer

ATTORNEY DOCKET NO. DASI.002.03US

1.	[X]	This Information Disclosure Statement is filed <u>before</u> the later of:				
		[X]	three months from the filing date of a national application other than a continued prosecution application under §1.53(d);			
		[]	three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application;			
		[]	the mailing of a first office action on the merits; or			
		[]	the mailing of a first Office Action after the filing of request for continued examination under §1.114.			
	[X]	In acc	cordance with 37 C.F.R. § 1.97(b), no fee is required.			
2.	[]		information Disclosure Statement is filed after the events noted in paragraph before either:			
		[]	a final action under 37 C.F.R. § 1.113;			
		[]	a Notice of Allowance under 37 C.F.R. § 1.311; or			
		[]	an action that otherwise closes prosecution in the application.			
	[]	In acc	cordance with 37 C.F.R. § 1.97(c) also enclosed is:			
		[]	a fee under 37 C.F.R. § 1.17(p) in the amount of \$180.00; or			
		[]	a certification as stated below.			
3.	[]		nformation Disclosure statement is filed on or before the payment of the fee, but after either:			
		[]	a final action under 37 C.F.R. § 1.113;			
		[]	a Notice of Allowance under 37 C.F.R. § 1.311; or			
		[]	an action that otherwise closes prosecution in the application.			

PATENT []	ATTORNEY In accordance with 37 C.F.R. § 1.97(d) also enclosed is	DOCKET NO. DASI.002.03US	
	[] a certification, as stated below; and		
	[] a fee under 37 C.F.R §1.17(p) in the amount of	\$180.00.	
Certification	Ī		
The	undersigned also states:		
[]	[] Each item of information contained in the Information Disclosure Statement cited herein was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or		
[]	No item of information contained in the Information Dissubmitted herewith was cited in a communication from a counterpart foreign application or, to the knowledge of made reasonable inquiry, was known to any individual d § 1.56(c) more than three months prior to the filing date Disclosure Statement.	a foreign patent office in a the undersigned, having lesignated in 37 C.F.R.	
	The fees indicated above are:	\$	
		TOTAL FEES: \$	
[] A ch	eck including the amount of the above-indicated TOTAL F	FEES is attached.	
[] Pleas	Please charge Deposit Account No. 18-0020 in the amount of: \$		
[] A ch	A check in the amount of \$ is attached.		
[X] No fe	No fee is required.		
assoc	Commissioner is hereby authorized to charge any underpay ciated with this communication, including any necessary fee it any overpayment to Deposit Account No. 18-0020.		
[X]	Any filing fees under 37 C.F.R. § 1.16 for the presentation	of extra claims.	
[X]	Any patent application processing fees under 37 C.F.R. § 1	1.17.	

PATENT

ATTORNEY DOCKET NO. DASI.002.03US

[X] A duplicate copy of this sheet is attached for accounting purposes.

Respectfully submitted,

Dated: marw 7 2002

Barbara Rae-Venter, Ph.D.

Reg. No. 32,750

Rae-Venter Law Group, P.C. PO Box 1898 Monterey, CA 93942-1898

Phone: (831) 648-3090 Facsimile: (831) 242-0137

BRV/cs